MBX Biosciences
MBX
54.54
-2.38
-4.18%
MBX Biosciences
US · MBX
#2567 by market cap
Listed 2024
54.54
-2.38
-4.18%
Live - 5344 symbols - heartbeat 423s ago
· 2026-10-08 07:22
Pre-market
54.00
-0.99%
After-hours
54.32
-0.40%
Overnight
55.19
+1.19%
- Market cap
- 2.63B
- P/E (TTM)i
- -23.01
- P/Bi
- 6.41
- EPSi
- -2.38
- Div yieldi
- 0.00%
- 52W posi
- 70%
Reader sentiment
Are you bullish or bearish on MBX?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 4 years
Income statement
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- |
| Selling & admin expenses | 3.76M | 6.78M | 10.78M | 18.90M |
| Research & development | 21.40M | 28.53M | 57.42M | 79.16M |
| Operating profit | -25.16M | -35.31M | -68.19M | -98.06M |
| Pretax profit | -26.14M | -32.56M | -61.92M | -86.97M |
| Tax | -- | -- | -- | -- |
| Net profit | -26.14M | -32.56M | -61.92M | -86.97M |
| Basic EPS | -1 | -1 | -6 | -2 |
| Diluted EPS | -0.82 | -1.02 | -5.82 | -2.38 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 4.12M | 4.08M | 4.66M | 6.04M | 8.79M | 9.95M |
| Research & development | 22.41M | 17.72M | 19.27M | 19.76M | 18.47M | 30.99M |
| Operating profit | -26.53M | -21.81M | -23.93M | -25.80M | -27.27M | -40.93M |
| Pretax profit | -23.88M | -19.41M | -21.62M | -22.06M | -23.52M | -37.10M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -23.88M | -19.41M | -21.62M | -22.06M | -23.52M | -37.10M |
| Basic EPS | -1 | -1 | -1 | 0 | -1 | -1 |
| Diluted EPS | -0.71 | -0.58 | -0.63 | -0.49 | -0.50 | -0.78 |
Balance sheet
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total current assets | 44.21M | 83.47M | 267.29M | 381.54M |
| Cash & ST investments | 42.46M | 80.68M | 262.15M | 373.71M |
| Inventory | -- | -- | -- | -- |
| Total assets | 45.10M | 84.18M | 268.54M | 385.14M |
| Total current liabilities | 3.43M | 3.93M | 11.05M | 15.50M |
| Short-term debt | 137.00K | 153.00K | 171.00K | 172.00K |
| Long-term debt | -- | -- | -- | -- |
| Total liabilities | 87,700,000.00 | 156,648,000.00 | 11,093,000.00 | 15,921,000.00 |
| Total equity | -42.61M | -72.47M | 257.44M | 369.22M |
| Retained earnings | -43.02M | -75.58M | -137.51M | -224.48M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 244.28M | 229.19M | 397.50M | 381.54M | 448.54M | 427.86M |
| Cash & ST investments | 240.79M | 224.91M | 391.67M | 373.71M | 439.98M | 418.58M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 245.93M | 231.52M | 400.08M | 385.14M | 452.70M | 435.91M |
| Total current liabilities | 10.48M | 11.76M | 12.06M | 15.50M | 14.57M | 23.66M |
| Short-term debt | 130.00K | 138.00K | 154.00K | 172.00K | 178.00K | 631.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 10,504,000.00 | 12,283,000.00 | 12,538,000.00 | 15,921,000.00 | 14,945,000.00 | 26,370,000.00 |
| Total equity | 235.42M | 219.24M | 387.54M | 369.22M | 437.76M | 409.54M |
| Retained earnings | -161.39M | -180.80M | -202.41M | -224.48M | -247.99M | -285.09M |
Cash flow
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Operating cash flow | -23.12M | -31.98M | -54.68M | -79.95M |
| Depreciation & amortization | 56.00K | 157.00K | 244.00K | 248.00K |
| Free cash flow | -23.56M | -32.11M | -55.56M | -81.88M |
| Dividends paid | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 174.54M | 187.95M |
| Ending cash balance | 24.21M | 30.52M | 49.35M | 75.29M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -22.68M | -17.43M | -21.54M | -18.30M | -20.21M | -22.62M |
| Depreciation & amortization | 77.00K | 61.00K | 50.00K | 60.00K | 64.00K | 79.00K |
| Free cash flow | -22.71M | -18.14M | -21.94M | -19.09M | -20.65M | -23.52M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 187.95M | 0 | 85.37M | 254.00K |
| Ending cash balance | 29.90M | 39.78M | 223.13M | 75.29M | 45.42M | 54.33M |
Returns & efficiency
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| ROE %i | -- | -- | -66.95 | -27.76 |
| ROA %i | -57.96 | -50.38 | -35.11 | -26.61 |
| ROIC %i | -- | -- | -73.54 | -31.26 |
| 5-year avg ROE %i | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- |
| Current ratioi | 12.89 | 21.26 | 24.19 | 24.62 |
| Quick ratioi | 12.42 | 20.60 | 23.78 | 24.25 |
| Debt / assetsi | 1.02 | 0.38 | 0.06 | 0.15 |
| LT debt / equityi | -- | -- | -- | 0.11 |
| Interest coveragei | -68.88 | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -31.21 | -126.93 | -24.43 | -27.76 | -25.73 | -33.17 |
| ROA %i | -29.87 | -52.32 | -23.59 | -26.61 | -24.79 | -31.25 |
| ROIC %i | -34.56 | -141.60 | -27.55 | -31.26 | -29.30 | -37.27 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 23.31 | 19.50 | 32.95 | 24.62 | 30.79 | 18.08 |
| Quick ratioi | 23.11 | 19.20 | 32.60 | 24.25 | 30.42 | 17.82 |
| Debt / assetsi | 0.05 | 0.28 | 0.16 | 0.15 | 0.12 | 0.77 |
| LT debt / equityi | -- | 0.23 | 0.12 | 0.11 | 0.09 | 0.66 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-10-08 07:22:15 · For reference only, not investment advice and not tailored to your situation.